JP2023527621A5 - - Google Patents
Info
- Publication number
- JP2023527621A5 JP2023527621A5 JP2022555742A JP2022555742A JP2023527621A5 JP 2023527621 A5 JP2023527621 A5 JP 2023527621A5 JP 2022555742 A JP2022555742 A JP 2022555742A JP 2022555742 A JP2022555742 A JP 2022555742A JP 2023527621 A5 JP2023527621 A5 JP 2023527621A5
- Authority
- JP
- Japan
- Prior art keywords
- tag
- domain
- chimeric antigen
- receptor
- antigen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20163257.7 | 2020-03-16 | ||
| EP20163257.7A EP3881866A1 (en) | 2020-03-16 | 2020-03-16 | A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated response in a mammal |
| PCT/EP2021/056625 WO2021185807A1 (en) | 2020-03-16 | 2021-03-16 | A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated immune response in a mammal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527621A JP2023527621A (ja) | 2023-06-30 |
| JP2023527621A5 true JP2023527621A5 (cg-RX-API-DMAC7.html) | 2024-07-03 |
Family
ID=69844641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555742A Pending JP2023527621A (ja) | 2020-03-16 | 2021-03-16 | 哺乳類におけるキメラ抗原受容体媒介性免疫応答を刺激するための方法における使用のための、pd-l1および/またはpd-l2を含む標的化モジュール |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230183351A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3881866A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023527621A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115279407A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021237694A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3170250A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021185807A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115916250A (zh) * | 2020-05-20 | 2023-04-04 | 美天施生物科技有限两合公司 | 用于治疗表达cd90和cd326的癌症的组合物和方法 |
| WO2023060126A1 (en) * | 2021-10-06 | 2023-04-13 | Dana-Farber Cancer Institute, Inc. | Engineered cytokine receptors for tunable adoptive cell therapy |
| WO2025219955A1 (en) * | 2024-04-17 | 2025-10-23 | BioNTech SE | Soluble tcrs and methods of use thereof |
| WO2026119817A1 (en) * | 2024-12-02 | 2026-06-11 | BioNTech SE | Agents and methods for targeted delivery of immune effector cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX356367B (es) * | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| JP5897035B2 (ja) | 2010-12-14 | 2016-03-30 | ユニバーシティ オブ メリーランド,ボルチモア | 汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法 |
| US9708384B2 (en) | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| AU2014337367B2 (en) * | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Peptidic chimeric antigen receptor T cell switches and uses thereof |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| US11091546B2 (en) * | 2015-04-15 | 2021-08-17 | The Scripps Research Institute | Optimized PNE-based chimeric receptor T cell switches and uses thereof |
| EP3315511A1 (en) * | 2016-10-29 | 2018-05-02 | Miltenyi Biotec GmbH | Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens |
| LT3592769T (lt) * | 2017-03-09 | 2024-08-26 | Genmab A/S | Antikūnai, atpažįstantys pd-l1 |
| CA3065133A1 (en) * | 2017-06-09 | 2018-12-13 | Gemoab Monoclonals Gmbh | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders |
-
2020
- 2020-03-16 EP EP20163257.7A patent/EP3881866A1/en active Pending
-
2021
- 2021-03-16 CA CA3170250A patent/CA3170250A1/en active Pending
- 2021-03-16 EP EP21718798.8A patent/EP4121107A1/en active Pending
- 2021-03-16 WO PCT/EP2021/056625 patent/WO2021185807A1/en not_active Ceased
- 2021-03-16 US US17/911,678 patent/US20230183351A1/en active Pending
- 2021-03-16 JP JP2022555742A patent/JP2023527621A/ja active Pending
- 2021-03-16 AU AU2021237694A patent/AU2021237694A1/en active Pending
- 2021-03-16 CN CN202180021083.0A patent/CN115279407A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7700159B2 (ja) | Axlまたはror2に対するキメラ抗原受容体およびその使用方法 | |
| US12304935B2 (en) | Immunomodulatory polypeptides and related compositions and methods | |
| KR102898514B1 (ko) | 다양한 다중 항원의 표적화를 위한 역방향 범용 키메라 항원 수용체 발현 면역 세포, 이의 제조 방법 및 암, 감염증 및 자가면역 장애의 치료를 위한 이의 용도 | |
| KR102828999B1 (ko) | 비-hla 제한된 t 세포 수용체 및 이의 용도 | |
| JP2023091037A (ja) | Gタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 | |
| CN110035768A (zh) | 嵌合抗原受体 | |
| US20230183351A1 (en) | A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated immune response in a mammal | |
| JP2020525408A (ja) | 共通キメラ抗原受容体発現免疫細胞のためのターゲティングモジュールならびに癌、感染および自己免疫障害の処置における使用 | |
| CN112996819B (zh) | 细胞分选系统及使用方法 | |
| US20250302875A1 (en) | TARGETING MODULES AGAINST IL13R-alpha-2 AND/OR HER2 FOR USE IN A METHOD FOR STIMULATING A CHIMERIC ANTIGEN RECEPTOR-MEDIATED IMMUNE RESPONSE IN A MAMMAL | |
| KR20240034205A (ko) | 항EGFRviii 항체, 폴리펩타이드, 상기 폴리펩타이드를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법 및 상기 폴리펩타이드를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터 | |
| EP4296281A1 (en) | Targeting modules against cd123 and a tag for use in a method for stimulating a universal chimeric antigen receptor-mediated immune response in a mammal | |
| US20250269025A1 (en) | Targeting modules against cd123 for use in a method for stimulating a chimeric antigen receptor-mediated immune response in a mammal | |
| EP4566619A1 (en) | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal | |
| EP4382119A1 (en) | A kit for use in the treatment of hematological cancer | |
| JP2025524457A5 (cg-RX-API-DMAC7.html) | ||
| HK40125822A (en) | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal | |
| KR20240035506A (ko) | 키메라 항원 수용체, 상기 수용체를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법, 및 상기 키메라 항원 수용체를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터 | |
| CN120882422A (zh) | 一种用于治疗血液癌症的试剂盒 | |
| HK40109914A (en) | Anti-egfrviii antibody, polypeptide, cell capable of expressing said polypeptide, pharmaceutical composition containing said cell, method for producing said cell, and polynucleotide or vector comprising nucleotide sequence encoding said polypeptide | |
| CN122011207A (zh) | 过表达h2a.z的car-t细胞及其制备方法和应用 |